This Stock Is Already Up 58% This Year. Is It a Buy?

The past few years have been challenging for Moderna (NASDAQ: MRNA) as the biotech has failed to maintain strong revenue growth from its coronavirus vaccine. The company's shares have significantly lagged the market since 2022. However, the biotech is off to a strong start in 2026. Moderna stock is already trading up 58% this year. Could this finally be the start of a sustained bull run for the pharmaceutical stock? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the ...